Literature DB >> 33239810

Will the reclassification of multiple myeloma change how people are treated?

Benjamin Plackett.   

Abstract

Entities:  

Keywords:  Cancer; Drug discovery; Health care

Year:  2020        PMID： 33239810     DOI： 10.1038/d41586-020-03224-1

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  4 in total

1.  Improved long-term survival in multiple myeloma up to the age of 80 years.

Authors:  S Y Kristinsson; W F Anderson; O Landgren
Journal:  Leukemia       Date:  2014-01-14       Impact factor: 11.528

Review 2.  Molecular pathogenesis of multiple myeloma and its premalignant precursor.

Authors:  W Michael Kuehl; P Leif Bergsagel
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 3.  Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?

Authors:  Mattia D'Agostino; Noopur Raje
Journal:  Leukemia       Date:  2019-11-28       Impact factor: 11.528

4.  Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk.

Authors:  Jill Corre; Lydia Montes; Elodie Martin; Aurore Perrot; Denis Caillot; Xavier Leleu; Karim Belhadj; Thierry Facon; Cyrille Hulin; Mohamad Mohty; Jean Fontan; Margaret Macro; Sabine Brechignac; Arnaud Jaccard; Anne-Marie Stoppa; Frederique Orsini-Piocelle; Didier Adiko; Laurent Voillat; Faiza Keddar; Marly Barry; Helene Demarquette; Marie-Noelle Certain; Isabelle Plantier; Murielle Roussel; Benjamin Hébraud; Thomas Filleron; Michel Attal; Hervé Avet-Loiseau
Journal:  Haematologica       Date:  2020-09-01       Impact factor: 9.941
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.